DNA vs. NMRA, TARS, VIR, INBX, BCRX, FUSN, FDMT, SANA, CGON, and BEAM
Should you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Neumora Therapeutics (NMRA), Tarsus Pharmaceuticals (TARS), Vir Biotechnology (VIR), Inhibrx (INBX), BioCryst Pharmaceuticals (BCRX), Fusion Pharmaceuticals (FUSN), 4D Molecular Therapeutics (FDMT), Sana Biotechnology (SANA), CG Oncology (CGON), and Beam Therapeutics (BEAM). These companies are all part of the "biological products, except diagnostic" industry.
Neumora Therapeutics (NASDAQ:NMRA) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.
Neumora Therapeutics has a net margin of 0.00% compared to Neumora Therapeutics' net margin of -409.11%. Ginkgo Bioworks' return on equity of 0.00% beat Neumora Therapeutics' return on equity.
In the previous week, Ginkgo Bioworks had 4 more articles in the media than Neumora Therapeutics. MarketBeat recorded 8 mentions for Ginkgo Bioworks and 4 mentions for Neumora Therapeutics. Ginkgo Bioworks' average media sentiment score of 1.24 beat Neumora Therapeutics' score of 0.16 indicating that Neumora Therapeutics is being referred to more favorably in the media.
Neumora Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks.
47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 26.4% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 15.1% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Neumora Therapeutics currently has a consensus target price of $22.57, indicating a potential upside of 137.34%. Ginkgo Bioworks has a consensus target price of $1.90, indicating a potential upside of 204.05%. Given Neumora Therapeutics' higher probable upside, analysts clearly believe Ginkgo Bioworks is more favorable than Neumora Therapeutics.
Ginkgo Bioworks received 13 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 47.92% of users gave Ginkgo Bioworks an outperform vote.
Summary
Neumora Therapeutics beats Ginkgo Bioworks on 9 of the 14 factors compared between the two stocks.
Get Ginkgo Bioworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ginkgo Bioworks Competitors List
Related Companies and Tools
